Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric P Krenning

Showing results (91-100 of 173) with videos related to

Pageof 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenograftsMonique de Visser, Wytske M van Weerden, Corrina M A de Ridder, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 15, 2004
Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analoguesRaffaella Barone, Stanislas Pauwels, Joëlle De Camps, et al.
Journal of Medicinal Chemistry|July 10, 2014
[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumorsTheodosia Maina, Renzo Cescato, Beatrice Waser, et al.
Pharmaceuticals (Basel, Switzerland)|March 23, 2019
Localization of <sup>99m</sup>Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological ResponsesAikaterini Kaloudi, Emmanouil Lymperis, Panagiotis Kanellopoulos, et al.
International Journal of Cancer|February 6, 2003
Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases modelWouter A P Breeman, Amir Mearadji, Astrid Capello, et al.
Seminars in Nuclear Medicine|March 7, 2006
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumorsRoelf Valkema, Stanislas Pauwels, Larry K Kvols, et al.
European Journal of Medicinal Chemistry|January 1, 2014
[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targetingAikaterini Tatsi, Theodosia Maina, Renzo Cescato, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 7, 2014
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in micePanteleimon J Marsouvanidis, Marleen Melis, Erik de Blois, et al.
The Journal of Clinical Endocrinology and Metabolism|February 12, 2002
Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapyInge M van der Sluis, Annemieke M Boot, Eric P Krenning, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
Pageof 18

Showing results (91-100 of 173) with videos related to

Sort By:
Pageof 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenograftsMonique de Visser, Wytske M van Weerden, Corrina M A de Ridder, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 15, 2004
Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analoguesRaffaella Barone, Stanislas Pauwels, Joëlle De Camps, et al.
Journal of Medicinal Chemistry|July 10, 2014
[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumorsTheodosia Maina, Renzo Cescato, Beatrice Waser, et al.
Pharmaceuticals (Basel, Switzerland)|March 23, 2019
Localization of <sup>99m</sup>Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological ResponsesAikaterini Kaloudi, Emmanouil Lymperis, Panagiotis Kanellopoulos, et al.
International Journal of Cancer|February 6, 2003
Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases modelWouter A P Breeman, Amir Mearadji, Astrid Capello, et al.
Seminars in Nuclear Medicine|March 7, 2006
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumorsRoelf Valkema, Stanislas Pauwels, Larry K Kvols, et al.
European Journal of Medicinal Chemistry|January 1, 2014
[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targetingAikaterini Tatsi, Theodosia Maina, Renzo Cescato, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 7, 2014
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in micePanteleimon J Marsouvanidis, Marleen Melis, Erik de Blois, et al.
The Journal of Clinical Endocrinology and Metabolism|February 12, 2002
Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapyInge M van der Sluis, Annemieke M Boot, Eric P Krenning, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
Pageof 18